<DOC>
	<DOCNO>NCT00850252</DOCNO>
	<brief_summary>This study ass safety efficacy completely autologous completely biological tissue engineer blood vessel ( TEBV ) call Lifeline™ use arteriovenous fistula dialysis access .</brief_summary>
	<brief_title>Use Lifeline Graft A-V Shunt Model</brief_title>
	<detailed_description />
	<mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
	<criteria>Have sign inform consent Patients ≥ 21 year old Patients candidate BresciaCimino AV fistula ( vessel ) Have AV shunt fistula likely fail within 12 month : Signs clinical dysfunction : increment venous pressure , limited site puncture , stenosis , aneurysm dilatation surgically repair medium , Previous angioplasty , Previous thrombolysis Fall category ASA grade 2 ( UK equivalent ) Are willing able comply 2 , 4 , 6 , 8 , 10 , 12 , 16 , 20 , 24 , 36 52 week follow able comply biannual follow thereafter . A need urgent surgery Penicillin allergy Patients uncontrolled hypertension Morbid obesity ( &gt; 300 lb ) Active systemic infection Contraindication anticoagulation Coagulopathy Acute renal failure Connective tissue disease ( i.e . Marfan 's syndrome ) Pregnant nurse Life expectancy &lt; 1 year Participation another study involve investigational device new drug Other medical , social psychological issue , opinion principal investigator , preclude receive treatment procedures/evaluations postoperative follow Inability unwillingness comply schedule followup visit</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Lifeline</keyword>
	<keyword>Tissue engineer blood vessel</keyword>
	<keyword>A-V shunt</keyword>
</DOC>